New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 20, 2012
11:08 EDTDANOY, PFE, MJN, SYUT, NSRGYDanone drops following report of raised bid for Pfizer unit
Groupe Danone (DANOY) is retreating after the French food maker increased its offer for Pfizer's (PFE) infant nutrition business to close to $11B, according to Reuters, which cited the French website WanSquare. Danone is trying to outbid Nestle (NSRGY), which was nearing a deal for the Pfizer unit last week, Reuters reported, citing unnamed sources. Pfizer's infant nutrition business is growing quickly and is strong in emerging markets, with a key position in China, Reuters added. In late morning trading, Danone dropped 27c, or 1.91%, to $13.89. Pfizer (PFE) is climbing, while Mead Johnson (MJN) and Synutra (SYUT), which also sell infant formula, advanced.
News For DANOY;PFE;MJN;SYUT;NSRGY From The Last 14 Days
Check below for free stories on DANOY;PFE;MJN;SYUT;NSRGY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 22, 2014
16:18 EDTPFEPuma Biotech now responsible for R&D expenses associated with legacy trials
Subscribe for More Information
14:25 EDTMJNMead Johnson calls active after WSJ says Danone seeking expansion
Subscribe for More Information
14:23 EDTMJN, DANOYMead Johnson jumps after WSJ says Danone started strategic review
Shares of Mead Johnson (MJN) are moving higher after the Wall Street Journal reported that Danone (DANOY) has launched a strategic review. The French company has asked its top managers to explore expansion opportunities, The Journal stated, citing a person familiar with the matter. Shares of Mead Johnson, which reported its Q2 earnings earlier today, spiked 5%, or $4.91, to $97.18 following the report. WhiteWave Foods (WWAV) also moved higher following the report.
14:15 EDTDANOY, MJNMead Johnson spikes after WSJ says Danone seeking expansion opportunities
14:14 EDTMJNMead Johnson rallies to high of the day, up 6% to $98.10
Subscribe for More Information
13:47 EDTDANOYDanone unveils review to examine growth opportunities, WSJ says
Danone has unveiled a strategic review as CEO Franck Riboud looks to ensure its long-term growth, amid renewed speculation regarding whether the French company can survive as a stand-alone firm, according to The Wall Street Journal, citing a person familiar with the matter. Reference Link
07:32 EDTMJNMead Johnson sees FY14 EPS $3.65-$3.72, consensus $3.70
Subscribe for More Information
07:31 EDTMJNMead Johnson reports Q2 adjusted EPS 88c consensus 89c
Subscribe for More Information
July 18, 2014
07:40 EDTMJNMead Johnson August volatility elevated as shares near record high into Q2
Subscribe for More Information
06:41 EDTNSRGYNestle U.S. chocolate goals curbed by Lindt acquisition, Bloomberg says
Nestle, who usually aims to be first or second in all of its divisions, isnít even close in the U.S. chocolate candy industry, where the Swiss firm is shut-out by Mars and Hershey (HSY), reported Bloomberg. When Lindt & Spruengli finalizes its acquisition of Russell Stover Candies, Nestle will fall even deeper behind, by ranking fourth in the U.S. Reference Link
06:26 EDTDANOYDanone to buy 40% stake in Brookside Dairy
Subscribe for More Information
06:17 EDTMJNMead Johnson risk/reward favorable into Q2 results, says Citigroup
Subscribe for More Information
July 17, 2014
08:08 EDTPFEBristol-Myers, Pfizer announce enrollment in Phase IV EMANATE trial for Eliquis
Subscribe for More Information
July 16, 2014
10:36 EDTPFETreasury calls on Congress to halt inversion deals
Subscribe for More Information
09:27 EDTPFEPfizer to acquire InnoPharma for upfront cash payment of $225M
Subscribe for More Information
07:59 EDTPFETreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
07:04 EDTPFEPfizer says primary endpoint met in Phase 3 study of BeneFIX
Pfizer announced the positive results of a Phase 3 study comparing a prophylaxis regimen of BeneFIX Coagulation Factor IX 100 IU/kg once-weekly to on-demand treatment in people with moderately severe to severe hemophilia B. The top-line results of the study showed that the primary study endpoint was met and hemophilia B patients taking once-weekly BeneFIX showed a statistically significant reduction in the annualized bleeding rate relative to on-demand treatment with BeneFIX. In the study, the median ABR value, a commonly used measure of efficacy for prophylaxis regimens in hemophilia, was 2.0 for the prophylaxis regimen, compared to 33.6 for the on-demand regimen, representing a 94% decrease in bleeding rates. The mean ABR value was 3.6 for the prophylaxis period, compared to 32.9 for the on-demand treatment, which represents a reduction of 89%. Study results also showed that prophylaxis treatment significantly reduced both spontaneous and traumatic ABR compared to on-demand treatment with BeneFIX. In addition to meeting the primary endpoint, the secondary study endpoints showed that none of the 1,254 prophylaxis infusions administered during the study were associated with a less than expected therapeutic effect occurrence, which was defined as a spontaneous bleed occurring within 48 hours of a prophylaxis infusion. These results are preliminary, top-line data and are subject to additional analyses. Complete results from this study will be submitted for presentation at upcoming medical congresses and submitted for publication in a peer-reviewed journal.
July 15, 2014
10:00 EDTMJN, DANOYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
05:46 EDTMJNMead Johnson upgraded to Buy from Neutral at Goldman
Goldman Sachs upgraded Mead Johnson to Buy saying the company's results should beat expectations while it remains an attractive takeover candidate. Goldman raised its price target for shares to $107 from $91.
05:25 EDTDANOYDanone upgraded to Overweight from Equal Weight at Morgan Stanley
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use